The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP - PubMed (original) (raw)
. 2007 Mar 1;109(5):1857-61.
doi: 10.1182/blood-2006-08-038257. Epub 2006 Nov 14.
Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J Savage, Tamara Shenkier, Judy Sutherland, Randy D Gascoyne, Joseph M Connors
Affiliations
- PMID: 17105812
- DOI: 10.1182/blood-2006-08-038257
Free article
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H Sehn et al. Blood. 2007.
Free article
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, with patients exhibiting a wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP)has led to a marked improvement in survival and has called into question the significance of previously recognized prognostic markers. Since randomized controlled trials of R-CHOP in DLBCL have included select subgroups of patients, the utility of the International Prognostic Index (IPI) has not been reassessed. We performed a retrospective analysis of patients with DLBCL treated with R-CHOP in the province of British Columbia to assess the value of the IPI in the era of immunochemotherapy. The IPI remains predictive, but it identifies only 2 risk groups. Redistribution of the IPI factors into a revised IPI (R-IPI) provides a more clinically useful prediction of outcome. The R-IPI identifies 3 distinct prognostic groups with a very good (4-year progression-free survival [PFS] 94%, overall survival [OS] 94%), good (4-year PFS 80%, OS 79%), and poor (4-year PFS 53%, OS 55%) outcome, respectively (P < .001). The IPI (or R-IPI) no longer identifies a risk group with less than a 50% chance of survival. In the era of R-CHOP treatment, the R-IPI is a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials.
Similar articles
- Metabolic tumour area: a novel prognostic indicator based on 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma in the R-CHOP era.
Cui S, Xin W, Wang F, Shao X, Shao X, Niu R, Zhang F, Shi Y, Liu B, Gu W, Wang Y. Cui S, et al. BMC Cancer. 2024 Jul 25;24(1):895. doi: 10.1186/s12885-024-12668-x. BMC Cancer. 2024. PMID: 39054508 Free PMC article. - Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM. Savage KJ, et al. Ann Oncol. 2006 Jan;17(1):123-30. doi: 10.1093/annonc/mdj030. Epub 2005 Oct 19. Ann Oncol. 2006. PMID: 16236753 - Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI, Park MJ, Song HN, Kim HG, Kang MH, Lee HR, Kim Y, Kim RB, Lee SI, Lee GW. Go SI, et al. J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):567-576. doi: 10.1002/jcsm.12115. Epub 2016 Apr 12. J Cachexia Sarcopenia Muscle. 2016. PMID: 27104110 Free PMC article. - Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge.
Lavacchi D, Landini I, Perrone G, Roviello G, Mini E, Nobili S. Lavacchi D, et al. Pharmacol Ther. 2022 Jan;229:107924. doi: 10.1016/j.pharmthera.2021.107924. Epub 2021 Jun 24. Pharmacol Ther. 2022. PMID: 34175369 Review. - Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification.
Westin JR, Fayad LE. Westin JR, et al. Curr Hematol Malig Rep. 2009 Oct;4(4):218-24. doi: 10.1007/s11899-009-0029-y. Curr Hematol Malig Rep. 2009. PMID: 20425411 Review.
Cited by
- Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma.
Rebière V, Maajem M, Le Calloch R, Raj L, Le Bris AS, Malou M, Salmon F, Quintin-Roué I, Tempescul A, Bourhis D, Samaison L, Saad H, Salaun PY, Berthou C, Ianotto JC, Abgral R, Eveillard JR. Rebière V, et al. Front Nucl Med. 2022 Apr 7;2:829138. doi: 10.3389/fnume.2022.829138. eCollection 2022. Front Nucl Med. 2022. PMID: 39354989 Free PMC article. - Association of overall survival benefit of radiotherapy with progression-free survival after chemotherapy for diffuse large B-cell lymphoma: A systematic review and meta-analysis.
Wang J, Liu X, Wu Y, Zhong Q, Wu T, Yang Y, Chen B, Jing H, Tang Y, Jin J, Liu Y, Song Y, Fang H, Lu N, Li N, Zhai Y, Zhang W, Deng M, Wang S, Chen F, Yin L, Hu C, Qi S, Li Y. Wang J, et al. J Natl Cancer Cent. 2024 Apr 23;4(3):249-259. doi: 10.1016/j.jncc.2024.04.002. eCollection 2024 Sep. J Natl Cancer Cent. 2024. PMID: 39281722 Free PMC article. - Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients.
Candelaria M, Cerrato-Izaguirre D, Gutierrez O, Diaz-Chavez J, Aviles A, Dueñas-Gonzalez A, Malpica L. Candelaria M, et al. Int J Mol Sci. 2024 Aug 28;25(17):9328. doi: 10.3390/ijms25179328. Int J Mol Sci. 2024. PMID: 39273276 Free PMC article. - Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma.
Maas CCHM, van Klaveren D, Durmaz M, Visser O, Issa DE, Posthuma EFM, Zijlstra JM, Chamuleau MED, Lugtenburg PJ, Kersten MJ, Dinmohamed AG. Maas CCHM, et al. Blood Cancer J. 2024 Sep 12;14(1):157. doi: 10.1038/s41408-024-01137-0. Blood Cancer J. 2024. PMID: 39266543 Free PMC article. - Predictive value of prognostic nutritional index as prognostic biomarkers in patients with lymphoma: a systematic review and meta-analysis.
Liu X, Duan Y, Wang Y, Zhang X, Lv H, Li Q, Qiao N, Meng H, Lan L, Liu X, Liu X. Liu X, et al. Clin Transl Oncol. 2024 Sep 1. doi: 10.1007/s12094-024-03687-y. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39217595 Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials